Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 524164 | NSE Symbol : IOLCP | ISIN : INE485C01029 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
06-May-2025	16-May-2025	Quarterly Results	IOL Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2025 inter alia to consider and approve Audited Financial Results of the Company for the quarter and year ended 31st March 2025 Audited Financial Results for the quarter and year ended 31st March 2025 (As Per BSE Announcement Dated on: 16.05.2025)
04-Feb-2025	12-Feb-2025	Quarterly Results	IOL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2025 inter alia to consider and approve the Un-Audited Financial Results of the Company for the Quarter and nine months ended 31st December 2024 and declare payment of Interim Dividend for FY 2024-25 if any. Outcome of the Board Meeting (As Per BSE Announcement dated on 12.02.2025)
18-Dec-2024	27-Dec-2024	Stock Split	IOL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/12/2024 inter alia to consider and approve The meeting of the Board of Directors is scheduled to be held on Friday the 27th December 2024 inter-alia to consider and approve the alteration in the share capital of the Company by sub-division / split of existing equity shares having face value of Rs. 10/- each fully paid up as may be determined by the Board of Directors. Board of Directors of the Company, at its meeting held on 27th December 2024, has approved, inter alia, the sub-division / split of each equity share of face value of Rs. 10/- (Rupees Ten only) each, fully paid-up into 5 (Five) equity shares of face value of Rs. 2/- (Rupee two only) each, fully paid-up, by alteration of Capital Clause of the Memorandum of Association of the Company. The proposed sub-division/split is subject to the approval of the Shareholders through Postal Ballot process. The Record Date for determining eligibility for the sub-division/split will be communicated in due course. (As Per BSE Announcement Dated on 27.12.2024)
05-Nov-2024	14-Nov-2024	Quarterly Results	IOL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve the Un-Audited Financial Results of the Company for the Quarter and Half Year ended 30th September 2024
28-Oct-2024	28-Oct-2024	Change in Directors	Appointment of Ms Rajni Jha as an Additional and Independent Director of the Company Pursuant to the provisions of the Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform you that the Board of Directors of the Company, at their Meeting held today i.e. 28th October 2024 inter-alia, approved the following: 1. Appointment of Ms Rajni Jha (DIN: 10818947) as an Additional and Independent Director of the Company for a term of three years, with effect from 28th October 2024, subject to approval of Members of the Company. 2. Approved the Postal Ballot Notice to seek the approval of the shareholders through Postal Ballot for appointment of Ms Rajni Jha as Independent Director of the Company. Read less..
30-Jul-2024	09-Aug-2024	Quarterly Results	IOL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve Financial Results of the Company for the Quarter ended 30th June 2024 Un-Audited Financial Results for the quarter ended 30th June 2024 (As Per BSE Announcement Dated on: 08/08/2024)
06-May-2024	14-May-2024	Accounts	IOL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2024 inter alia to consider and approve the Audited Financial Results of the Company for the Quarter and Year ended 31st March 2024 Outcome of the Board meeting dated 14th May 2024 (As per BSE Announcement Dated on 14/05/2024)
29-Jan-2024	06-Feb-2024	Quarterly Results	IOL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2024 inter alia to consider and approve Audited Financial Results of the Company for the quarter and nine months ended 31st December 2023 and declaration of Interim Dividend if any for the Financial Year 2023-2024. The Board of Directors in its meeting held on 6th February 2024 declared an Interim dividend of Rs 5/- (50%) per equity share of face value of Rs 10/-each for the Financial year 2023-24 Audited Financial Results for the quarter and nine months ended 31st December 2023 Pursuant to Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on today i.e. 6th February 2024 has inter alia considered and approved: 1. The Standalone & Consolidated Audited Financial Results for the quarter and nine months ended 31st December 2023. Copy of the said Financial Results along with unmodified Auditors Report thereon is enclosed herewith as 'Annexure - 1'. 2. Declared an Interim Dividend of Rs. 5/- (50%) per Equity Share of Face Value Rs.10/- each for the Financial Year 2023-24. 3. Fixed 16th February 2024 as the Record Date to determine the names of the equity shareholders, who shall be entitled to receive the above said Interim Dividend. The payment of the Interim Dividend shall be made to the eligible shareholders with in 30 days of declaration of dividend. 4. Closing of M/s IOL Global Limited, UK, Wholly Owned Subsidiary of the Company. (As Per BSE Announcement Dated on 06.02.2024)
30-Oct-2023	08-Nov-2023	Quarterly Results	IOL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve the Audited Financial Results of the Company for the Quarter and half year ended 30th September 2023 Dear Sir, Pursuant to Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on today i.e. 8th November 2023 has inter alia considered and approved the Audited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September 2023. The Audited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September 2023 along with Auditors Report thereon is enclosed herewith. We hereby confirm and declare that Auditors Report issued by the Statutory Auditors on the financial results of the Company for the quarter and half year ended 30th September 2023 is an Unmodified Report. The meeting of Board of Directors commenced at 12:30 PM and concluded at 3:50 PM. The above Audited Financial Results are also available on the website of the Company i.e. www.iolcp.com. Please find attached herewith Audited Financial Results for the quarter and half year ended 30th September 2023 (As Per BSE Announcement Dated on 08/11/2023) Intimation under Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement Dated on 10.11.2023)
03-Aug-2023	09-Aug-2023	Quarterly Results	IOL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2023 inter alia to consider and approve Audited Financial Results for the quarter ended 30th June 2023 Pursuant to Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on today i.e. 9th August 2023 has inter alia considered and approved the Audited Financial Results (Standalone & Consolidated) for the Quarter ended 30th June 2023. The Audited Financial Results (Standalone & Consolidated) for the Quarter ended 30th June 2023 along with unmodified Auditors Report thereon is enclosed herewith. We hereby confirm and declare that Auditors Report issued by the Statutory Auditors on the financial results of the Company for the Quarter ended 30th June 2023 is an Unmodified Report. The meeting of Board of Directors commenced at 04:00 PM and concluded at 5:50 PM. The above Audited Financial Results are also available on the website of the Company i.e. www.iolcp.com. (As per BSE Announcement Dated on 09/08/2023)
21-Apr-2023	28-Apr-2023	Quarterly Results	IOL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/04/2023 inter alia to consider and approve the Audited Financial Results of the Company for the Quarter and year ended 31st March 2023 Audited Financial Results (Standalone & Consolidated) for the Quarter and Year ended 31st March 2023 Outcome of the Board Meeting dated 28th April 2023 (As Per BSE Announcement dated on 28.04.2023)
03-Apr-2023	03-Apr-2023	Change in Directors	Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on today i.e. 3rd April 2023 has inter alia has: 1. Approved the change of the designation of Mr Vikas Gupta from Executive Director to Joint Managing Director of the Company. 2. Appointed Mr Abhiraj Gupta as Additional Director in the category of Executive Director with effect from 3rd April 2023. 3. Appointed Mr Vikas Vij as Chief Executive Officer (CEO) of the Company with effect from 3rd April 2023. 4. Took note of the resignation of Dr Sanjay Chaturvedi (DIN: 08927689) from the position of Executive Director & CEO of the Company and accorded their approval to relieve Dr. Sanjay Chaturvedi from the closure of business hours on 3rd April 2023. 5. Took note of the completion of Unit 9, a multi-product manufacturing facility at Barnala Plant site.
01-Feb-2023	07-Feb-2023	Quarterly Results	IOL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2023 inter alia to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the next meeting of the Board of Directors is scheduled to be held on Tuesday the 7th February 2023 inter-alia to consider and approve the Audited Financial Results of the Company for the Quarter and nine months ended 31st December 2022 and declaration of Interim Dividend if any for the Financial Year 2022-2023. Further pursuant to the requirements of SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys 'Code of Conduct to Regulate Monitor and Reporting of Trading by Designated Persons' the Trading Window which is closed with effect from 01st January 2022 shall continue to close till the expiry of 48 hours from the date of financial results for Quarter and nine months ended 31st December 2022 are made public. Accordingly the trading window shall reopen on the 10th February 2023. Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our letter dated 1st February 2023, we wish to inform you that the Board of Directors in its meeting held on today i.e. 7th February 2023 has inter alia considered and approved: 1. The Audited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 31st December 2022. Copy of the said Financial Results along with unmodified Auditors Report thereon is enclosed herewith as 'Annexure - 1'. 2. Declared an Interim Dividend of Rs. 4/- (Rupees four only) per Equity Share of Face Value Rs.10/- each for the Financial Year 2022-23. 3. Fixed 17th February 2023 (Friday) as the Record Date to determine the names of the equity shareholders, who shall be entitled to receive the above said Interim Dividend. The payment of the Interim Dividend shall be made to the eligible shareholders before 8th March 2023. We wish to inform you that the Board of Directors in its meeting held on today i.e. 7th February 2023 has inter alia considered and approved: Declared an Interim Dividend of Rs. 4/- (Rupees four only) per Equity Share of Face Value Rs.10/- each for the Financial Year 2022-23. Fixed 17th February 2023 (Friday) as the Record Date to determine the names of the equity shareholders, who shall be entitled to receive the above said Interim Dividend. The payment of the Interim Dividend shall be made to the eligible shareholders before 8th March 2023. (As Per BSE Announcement Dated on 07.02.2023)
03-Nov-2022	14-Nov-2022	Quarterly Results	IOL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the next meeting of the Board of Directors is scheduled to be held on Monday the 14th November 2022 inter-alia to consider and approve the Audited Financial Results of the Company for the Quarter ended 30th September 2022. Further pursuant to the requirements of SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Conduct to Regulate Monitor and Reporting of Trading by Designated Persons the Trading Window which is running closed with effect from 1st October 2022 shall continue to remain close till the expiry of 48 hours from the date of Audited Financial Results for Quarter ended 30th September 2022 are made public. Accordingly the trading window shall reopen on 17th November 2022. Pursuant to Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on today i.e. 14th November 2022 has inter alia considered and approved: 1. The Audited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September 2022. Copy of the said Financial Results along with unmodified Auditors Report thereon is enclosed herewith as Annexure 1. 2. Conversion of Unit 9 as multiproduct facility to manufacture other pharma products. We hereby confirm and declare that Auditors Report issued by the Statutory Auditors on the financial results of the Company for the quarter and half year ended 30th September 2022 is an Unmodified Report. The meeting of Board of Directors commenced at 4:30 PM and concluded at 6:15 PM. The above Audited Financial Results are also available on the website of the Company i.e. www.iolcp.com. (As Per BSE Announcement Dated on 14.11.2022) Submission of newspaper publication of Audited Financial Results for the quarter and half year ended 30th September 2022 Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As per BSE Announcement Dated on 15/11/2022)
22-Sep-2022	22-Sep-2022	Others	Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on today i.e. 22nd September 2022 has inter alia considered and approved to invest US$ 2.1 Million in USpharma Limited an USA based Company subject to compliance with Foreign Exchange Management (Overseas Investment) Rules, 2022 and Foreign Exchange Management (Overseas Investment) Regulations, 2022. USpharma Ltd., is an USA based Company that develop novel drug delivery technologies. The meeting of Board of Directors commenced at 6:00 PM and concluded at 6:42 PM. This is for your information & record.

1 2

LOGIN HERE

IOL Chemicals & Pharmaceuticals Ltd

Board Meeting